Thrombolytic therapy alleviates pulmonary embolism (PE) symptoms rapidly but increases bleeding risk, with no consistent consensus on acute intermediate-high risk PE. This study evaluated the efficacy and safety of low-dose prolonged infusion thrombolysis for acute intermediate-high risk PE to provide a safer clinical option. 

Pulmonary Hypertension (PH) is a chronic disease that causes significant structural deterioration in the right atrium and ventricle. In the past 1–2 decades, life expectancy in patients with PH has increased due to improved awareness, diagnosis and advancements in treatment.

In this PH Community Call, we discussed: 

• Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease
• Ferroportin Inhibition Attenuates Pulmonary Hypertension in Hypoxic Sickle Cell Disease Mice 
• Artificial Intelligence-Based Echocardiography in Pulmonary Arterial Hypertension 

Patients with pulmonary arterial hypertension (PAH) experience long diagnostic delays, high functional class at diagnosis and poor prognosis. We aimed to study the differentiative and predictive value of 90 inflammatory and immunomodulatory related proteins in idiopathic and hereditary PAH (IPAH/HPAH) and systemic sclerosis-associated PAH (SSc-APAH). 

Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) has a poorer prognosis than idiopathic PAH, potentially attributable to pulmonary veno-occlusive disease (PVOD)-like involvement. 

Presented at PVRI 2026 Congress by Eric Austin, Vanderbilt University Medical Center

Presented at PVRI 2026 Congress by James Klinger, Alpert Medical School of Brown University

Presented at PVRI 2026 Congress by Jair Tenorio, Institute of Medical & Molecular Genetics (INGEMM), La Paz University Hospital

Presented at PVRI 2026 Congress by Vasile Foris, Medical University of Graz

Presented at PVRI 2026 Congress by Stephen Archer, Queen's University